Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant for preventive treatment of menstrual migraine
CTR20250137Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atogepant in Catamenial Migraine (3 arms), sponsored by AbbVie Inc. Primary endpoint: Change in perimenstrual period migraine days. Started May 2025; status: active.
02
Drugs
atogepant
03
Conditions
Catamenial Migraine
Beyond the preview
Go deeper on CTR20250137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250137.